Bridging human molecular genetics, sarcolemmal bio-nanomechanics, and engineered cytoprotective peptide scaffolds to arrest disease progression in Limb-Girdle Muscular Dystrophy R4 (LGMD 2E).
β-sarcoglycan (35 kDa) is the indispensable anchor of the tetrameric complex (α, β, γ, δ). If β-sarcoglycan is missing or misfolded, the remaining subunits cannot incorporate and undergo ER-associated degradation (ERAD).
Without the structural shock absorber, routine muscle contractions create sarcolemmal micro-ruptures. Extracellular calcium floods in, activating μ- and m-calpains that enzymatically digest internal titin and troponin.
Chronic NF-κB inflammation triggers fibro-adipogenic progenitors (FAPs), turning functional muscle into scar tissue. High expression in cardiomyocytes also drives significant lifetime risk of dilated cardiomyopathy.
Targeting the exact molecular defects identified in Class 5 pathogenic sequencing (RefSeq: NM_000232.5).
Serine replaced by bulky phenylalanine disrupts ectodomain folding. The protein is produced but trapped in the ER and routed to ERAD.
Introduction of a premature termination codon (PTC) at residue 184 causes nonsense-mediated mRNA decay (NMD) and zero functional translation.
Targeted bio-nanomechanics engineered to seal membrane ruptures, quench calpain proteolysis, arrest fibrotic signaling, and preserve cardiac mitochondria.
Amphipathic α-helix that inserts into high-curvature contraction-induced lipid tears, acting as a molecular plug to halt extracellular Ca²⁺ influx. Appended with icosanedioic acid ([AEEA]2-γGlu-C20 diacid) for sustained albumin hitchhiking.
Hydrocarbon-stapled NEMO-binding domain with (S)-2-(4'-pentenyl)alanine crosslinked via ring-closing metathesis (RCM) at positions X1 (pos 5) and X2 (pos 9). Appended with octadecanedioic acid to block NF-κB/FAP fibro-adipogenic macrophage scarring.
Head-to-tail amide backbone cyclic pseudo-substrate inhibitor that selectively shields sarcomeric titin and troponin from hyperactivated μ-calpain without proteasome cross-toxicity or non-specific off-target cleavage.
Mitochondria-targeted aromatic-cationic tetrapeptide that selectively partitions into inner mitochondrial cardiolipin, preserving electron transport chain cristae architecture, preventing mPTP opening, and defending against dilated cardiomyopathy.
Coordinated pharmacokinetics aligning sustained albumin-bound sarcolemmal protection with daily mitochondrial energetics.
Co-administered as a combined formulation in sterile, isotonic buffered saline (pH 7.4) twice per week:
Maintains continuous therapeutic serum concentrations above the critical micelle/resealing concentration ($C_{\text{seal}}$) across routine physical locomotion.
Administered every morning upon waking to provide uninterrupted bioenergetic support:
Rapidly crosses cell membranes and targets cardiomyocyte cardiolipin to ensure stable ATP generation during daytime metabolic demand and suppress reactive oxygen species (ROS) leakage.
ActRIIB receptor decoys and myostatin inhibitors (e.g., bimagrumab, taldefgrobep alfa) as well as unshielded eccentric resistance loading are strictly contraindicated in unstabilized β-sarcoglycanopathy.
Driving myofiber hypertrophy or high-tension contractions while the sarcolemma lacks mechanical integrity induces massive membrane shearing, catastrophic extracellular Ca²⁺ influx, unconstrained calpain hyperactivation, and accelerated rhabdomyolysis. Sarcolemmal resealing must be biochemically confirmed via serum CK/myoglobin reductions prior to introducing any anabolic stimulus.
Full-length technical documentation configured for clinical consultation and custom solid-phase peptide synthesis (SPPS) manufacturing.
Single sharp peak; C18/C4 column; UV 214/220 nm.
Deconvoluted mass matches theoretical formula within ±0.5 Da.
Residual trifluoroacetate <0.1% w/w for clinical biocompatibility.
Kinetic chromogenic LAL assay; sterile lyophilized cake under N₂/Ar.
Complete clinical translation report detailing SGCB genetics, ERAD trafficking, calpain cascades, synchronized dosing schedules, and CRO synthesis parameters (≥98% purity).
Comparative benchmark detailing PPMO exon skipping, cell-penetrating peptide engineering (Pip6a), and foundational sarcolemmal stabilization principles.
| Biomarker / Modality | Schedule | Target Clinical Endpoint |
|---|---|---|
| Serum Creatine Kinase (CK) & Myoglobin | Baseline, Wk 2, 4, 12, 24 | ≥40% reduction from baseline; indicates reduced membrane micro-leakage. |
| Cardiac MRI (T1/ECV, LVEF) & hs-cTnI | Baseline, Wk 12, 24 | Myocardial strain stabilization; absence of progressive fibrosis in left ventricle. |
| Serum TGF-β1 & MMP-9 | Baseline, Wk 4, 12 | Biochemical validation of NBD-mediated fibro-adipogenic attenuation. |
| Urinary β2-microglobulin & Cystatin-C | Monthly | Proximal renal tubule safety monitoring (preventing megalin/cubilin saturation). |